期刊文献+

表达心脏SCN5A基因的人胚肾细胞钠电流特性及其对钠通道阻滞剂的反应性 被引量:2

Features of Cardiac Sodium Channel Expressed in Human Embryonic Kidney Cells and Its Response to Sodium Channel Blockers
暂未订购
导出
摘要 目的利用人胚肾293细胞表达心脏钠通道SCN5A基因并研究其钠电流特性和对钠通道阻滞剂的反应性。方法野生型SCN5A基因和SCN1B基因共表达于人胚肾293细胞,应用全细胞膜片钳技术记录给药(氟卡尼与利多卡因)前后的钠电流。结果 SCN5A基因转染效率约为60%;测试电压为-40mV时记录到钠电流峰值大小约为-8nA;100μmol/L的氟卡尼轻度抑制钠电流,使钠电流峰值减少(21.1±4.6)%[(-435.8±30.5)pA/pF vs.(-343.9±27.1)pA/pF,P<0.01];氟卡尼使钠通道激活曲线和失活曲线均呈负向移动,改变的幅值分别是-6.08mV[(-51.88±1.20)mVvs.(-57.96±0.79)mV,P<0.05]和-9.08mV[(-94.12±0.13)mVvs.(-103.20±0.11)mV,P<0.05];1Hz和10Hz频率刺激时,氟卡尼使钠电流分别减少(64.5±10.7)%和(83.5±12.2)%(P<0.01);30μmol/L利多卡因使钠通道失活后快恢复时间常数和慢恢复时间常数分别延长2倍和3倍。结论表达心脏钠通道SCN5A基因的人胚肾293细胞模型可用于基因特异性的钠通道阻滞剂安全性与药效学筛查。 Objective To investigate the features of the cardiac sodium channel (SCN5A) expressed in the human embry- onic kidney cells,and to test its response to the sodium channel blockers. Methods Wild-type SCN5A gene was co-expressed with SCN1B gene in human embryonic kidney cells and the membrane currents were measured using a whole-cell patch clamp technique in the absence or presence of flecainide and lidocaine. Results The transfection efficiency of SCN5A gene was about 60%. The peak sodium current amplitude recorded at a test pulse of -40 mV was -8 nA;the peak sodium current amplitude was decreased by (21.1±4. 6)% [(-435.8±30. 5) pA/pF vs. (-343.9±27. 1) pA/pF,P〈0.01] in the presence of 100 μmol/L flecainide. The treatment with flecainide resulted in a negative shift of both curves of the voltage dependence of activation [-6.08 mV,(-51.88±1.20) mV vs. (-57.96±0. 79) mV,P〈0.05] and of inactivation [-9.08 mV, (-94. 12±0. 13) mV vs. (-103.20±0. 11) mV,P〈0. 05]. At stimulus frequencies of 1 Hz and 10 Hz, flecainide produced (64.5± 10.7) % and (83.5±12.2) % (P〈0. 01) reduction in sodium current, respectively. The presence of 30 μmol/L lidocaine led to a 2-fold prolongation of the constant of fast recovery time and a 3-fold prolongation of the constant of slow recovery time from the inactivation status of the sodium channel. Conclusion The human embryonic kidney cells which express the cardiac sodium channel can be used to screen the safety and pharmacodynamics of gene-specific sodium channel blockers.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2013年第1期1-7,共7页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 国家自然科学基金资助项目(No.30973601 No.812101059) 武汉市青年科技晨光计划资助项目(No.200950431174) 教育部"新世纪优秀人才支持计划资助项目"(No.NCET-09-0376)
关键词 人胚肾细胞 心脏钠通道 SCN5A基因 钠通道阻滞剂 细胞模型 human embryonic kidney cell cardiac sodium channel SCN5A gene sodium channel blocker cell model
  • 相关文献

参考文献16

  • 1Shuraih M, Ai T, Vatta M, et al. A common SCN5A variantalters the responsiveness of human sodium channels to classI antiarrhymic agents[J]. J Cardiovasc Electrophysiol,2007,18(4):434-440.
  • 2Meadows L S,Isom L L. Sodium channels as macromolecularcomplexes : implications for inherited arrhythmia syndromes[J]. Cardiovasc Res, 2005.67(3) :448-458.
  • 3Abriel H, Kass R S. Regulation of the voltage-gated cardiacsodium channel Navi. 5 by interacting proteins [J] . TrendsCardiovasc Med,2005,15(1) .35-40.
  • 4The Cardiac Arrhythmia Suppression Trial (CAST) Investi-gators. Preliminary report : effect of encainide and flecainideon mortality in a randomized trial of arrhythmia suppressionafter myocardial in.arction[J]. N Engl J Med.1989,321(6):406-412.
  • 5Benhorin J’Taub R,Goldmit M,et al. Effects of flecainide inpatients with new SCN5A mutation: mutation-specific thera-py for long-QT syndrome [J] . Circulation, 2000, 101 (14):1698-1706.
  • 6European Heart Rhythm Association, European Associationfor Cardio-Thoracic Surgery,Camm A J,et al. Guidelines forthe management of atrial fibrillation: the task force for themanagement of atrial fibrillation of the European Society ofCardiology (ESC)[J]. Eur Heart J,2010.31(19) :2369-2429.
  • 7van der Werf C, Kannankeril P J, Sacher F, et al. Flecainidetherapy reduces exercise-induced ventricular arrhythmias inpatients with catecholaminergic polymorphic ventricular tach-ycardia[J]. J Am Coll Cardiol,2011,57(22) ;2244-2254.
  • 8Barajas-Martinez H,Hu D,Ontiveros G,et al. Biophysical andmolecular characterization of a novel de novo KCNJ2 muta-tion associated with Andersen-Tawil syndrome and cate-cholaminergic polymorphic ventricular tachycardia mimicry[J]. Circ Cardiovasc Genet,2011,4(1) .51-57.
  • 9Abriel H. Wehrens X H,Benhorin J,et al. Molecular pharma-cology of the sodium channel mutation D1790G linked to thelong-QT syndrome[J]. Circulation.2000,102(8) :921-925.
  • 10Bennett P B, Valenzuela C,Chen L Q,et al. On the molecularnature of the lidocaine receptor of cardiac Na+ chan-nels. Modification of block by alterations in the alpha-subunitffl-IV interdomain[J]. Circ Res,1995,77(3) :584-592.

二级参考文献3

共引文献8

同被引文献14

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部